Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain UTHR message board posts where the ticker symbol UTHR has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest UTHR SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-17-034273 Size: 7 KB
2017-12-11
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-17-034272 Size: 11 KB
2017-12-11
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-17-034143 Size: 4 KB
2017-12-07
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-17-033673 Size: 16 KB
2017-12-01
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-17-033336 Size: 16 KB
2017-11-28
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-17-032686 Size: 23 KB
2017-11-17
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-17-032643 Size: 7 KB
2017-11-17
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-17-031903 Size: 14 KB
2017-11-13
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-17-031493 Size: 4 KB
2017-11-07
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-17-031414 Size: 7 KB
2017-11-07
More UTHR SEC Filings


Related news from
Thu, 14 Dec 2017
13:07:18 +0000
See what the IHS Markit Score report has to say about United Therapeutics Corp.
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on December 12. Index (PMI) data, output in the Healthcare sector is rising.
Mon, 04 Dec 2017
14:03:49 +0000
What Analysts Recommend for United Therapeutics in November 2017
In November 2017, the U.S. Food and Drug Administration (or FDA) granted United Therapeutics’ (UTHR) Adcirca Pediatric exclusivity until May 21, 2018.
Mon, 04 Dec 2017
12:34:56 +0000
How Did United Therapeutics’ Tyvaso and Orenitram Perform in 3Q17?
In 3Q17, United Therapeutics’ (UTHR) Tyvaso generated revenues of $88.9 million, a ~13% decline on a year-over-year (or YoY) basis and a ~15% decline on a quarter-over-quarter basis.
Fri, 01 Dec 2017
21:35:11 +0000
How UTHR’s Remodulin, Adcirca, and Unituxin Performed in 3Q17
In 3Q17, United Therapeutics' (UTHR) Remodulin reported revenues of $187.3 million, which reflected ~23% growth on a year-over-year (or YoY) basis and ~19% growth on a quarter-over-quarter basis.
Fri, 01 Dec 2017
20:03:21 +0000
How United Therapeutics Performed in 3Q17
In 3Q17, United Therapeutics (UTHR) reported revenues of $445 million, a ~9% increase on a year-over-year (or YoY) basis.
Wed, 29 Nov 2017
18:10:35 +0000
United Therapeutics Corp. – Value Analysis (NASDAQ:UTHR) : November 29, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives United Therapeutics Corp. a score of 88. Our analysis is based on comparing United Therapeutics Corp. with the following peers – Eli Lilly and Company, Gilead Sciences, Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Portola Pharmaceuticals, Inc., Pfizer Inc., Baxter International Inc., Cytokinetics, Incorporated, GlaxoSmithKline plc Sponsored ... Read more <b>(Read more...)</b>
Tue, 28 Nov 2017
12:52:19 +0000
United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : November 28, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for United Therapeutics Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more <b>(Read more...)</b>
Wed, 22 Nov 2017
12:35:12 +0000
Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks
FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.
Tue, 21 Nov 2017
18:55:11 +0000
United Therapeutics gets much-needed reprieve with drug patent
Silver Spring-based United Therapeutics Corp. will have six more months of commercial exclusivity for Adcirca, one of its leading pulmonary arterial hypertension drugs set to lose part of its patent protection Tuesday. Just a day before the drug's patent was set to expire, the Food and Drug Administration said it would extend pediatric exclusivity to United Therapeutics (UTHR) through May 21 for its Adcirca tablets, which made up nearly a quarter of the local biotech's revenue last year. The FDA's decision, based on study results submitted by Eli Lilly and Co. (LLY), will delay any cheaper, generic version of Adcirca from being approved in the next six months.
Tue, 21 Nov 2017
15:08:03 +0000
United Therapeutics PAH Drug's Exclusivity Period Extended
United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.
Mon, 20 Nov 2017
11:00:00 +0000
United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca®
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Nov. 20, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has granted ...
Tue, 14 Nov 2017
14:56:00 +0000
SteadyMed Receives Favorable Ruling from U.S. Court of Appeals for the Federal Circuit
SAN RAMON, Calif., Nov. 14, 2017-- SteadyMed Ltd., a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral ...
Wed, 25 Oct 2017
11:20:00 +0000
Corporate News Blog - United Therapeutics Receives FDA Approval of Third Generation Nebulizer for Tyvaso Inhalation System
LONDON, UK / ACCESSWIRE / October 25, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for United Therapeutics Corp. (NASDAQ: UTHR ), following which we ...
Wed, 25 Oct 2017
10:35:00 +0000
United Therapeutics Corporation to Host Earnings Call
Work NEW YORK, NY / ACCESSWIRE / October 25, 2017 / United Therapeutics Corporation (NASDAQ: UTHR ) will be discussing their earnings results in their Q3 Earnings Call to be held on October 25, 2017 at ...
Wed, 25 Oct 2017
10:00:00 +0000
United Therapeutics Corporation Reports Third Quarter 2017 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 25, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, ...
Mon, 23 Oct 2017
10:00:00 +0000
United Therapeutics Announces FDA Approval Of Third Generation Nebulizer For The Tyvaso® Inhalation System
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2017 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced approval by the U.S. Food and Drug Administration (FDA) of a new inhalation device, called the TD-300/A, for use with Tyvaso® (treprostinil) Inhalation Solution (Tyvaso). Tyvaso was originally approved by the FDA for the treatment of pulmonary arterial hypertension (PAH) in 2009, under a New Drug Application covering a drug-device combination product consisting of Tyvaso drug product, as well as an ultrasonic nebulizer and accessories referred to as the Tyvaso Inhalation System.
Thu, 19 Oct 2017
10:00:00 +0000
United Therapeutics Corporation To Report Third Quarter 2017 Financial Results Before The Market Opens On Wednesday, October 25, 2017
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 19, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its third quarter 2017 financial results ...
Mon, 09 Oct 2017
14:39:45 +0000
United Therapeutics’s Net Profit Margins Are Expected to Narrow
In December 2014, United Therapeutics (UTHR) collaborated with DEKA Research & Development to develop a pre-filled and semi-disposable pump, RemUnity, for the continuous and subcutaneous administration ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This last year I have subscribed to two investment services, ValueForum and a well known income newsletter. ValueForum costs a little over 200 per year. The income newsletter costs about 400 per year. I am up 11% on investments made because I heard about them on ValueForum (of course, I do my own research on everything but the ideas came from ValueForum and there was always some discussion of the pros and cons of each investment on VF). I am down 8% on investments made because I heard about them from the income newsletter. I might also add that I often hear about breaking events immediately on ValueForum and a day or two later the same information is finally available from the newsletter. Hmmm...... which service is the better value?" more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards